Tiziana Life Sciences #TILS – Develops Novel Investigational Treatment For Patients Infected with COVID-19 April 9, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London — April 9, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it has developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting development…

Tiziana Life Sciences developing TZLS-501 as a potential treatment for Coronavirus patients March 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TSLA / AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure. Tiziana, a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of TZLS-501, with Novimmune, SA, a Swiss biotechnology company with whom it entered into a world-wide license for composition-of-matter in 2017.…

Tiziana Life Sciences (Nasdaq: TLSA; AIM: TILS) – TZLS-501 Potential Treatment of Certain Patients Infected with Coronavirus COVID-19 – Posted in: Tiziana Life Sciences (TILS)

New York/London, March 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter…

Tiziana Life Sciences #TILS – Develops Novel Investigational Treatment For Patients Infected with COVID-19 April 9, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences developing TZLS-501 as a potential treatment for Coronavirus patients March 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences (Nasdaq: TLSA; AIM: TILS) – TZLS-501 Potential Treatment of Certain Patients Infected with Coronavirus COVID-19 – Posted in: Tiziana Life Sciences (TILS)

Address

Contact

Social

LEGAL